Intravitreal pegaptanib sodium (Macugen) for treatment of myopic choroidal neovascularization: A morphologic and functional study

Michele Rinaldi, Flavia Chiosi, Roberto Dellêomo, Mario R. Romano, Francesco Parmeggiani, Francesco Semeraro, Massimo Menzione, Ciro Costagliola

Research output: Contribution to journalArticle

Abstract

BACKGROUND:: To report the morphologic and functional outcomes resulting from the use of intravitreal pegaptanib (IVP) sodium (Macugen) in patients with myopic choroidal neovascularization. METHODS:: An open-label, nonrandomized, prospective clinical trial was performed. Morphologic outcome, such as foveal thickness, was assessed by optical coherence tomography, whereas functional outcomes were assessed by best-corrected visual acuity and microperimetry. Treatment protocol consisted of 3 consecutive IVP (0.3 mg/0.05 mL; baseline, 6th week, and 12th week). Follow-up checks were scheduled at the following intervals: baseline, 18, 24, 36, and 48 weeks. RESULTS:: Twenty eyes from 20 patients were studied. All patients completed follow-up at 48 weeks. After IVP, a significant decrease in foveal thickness occurred (-20%), and at the end of follow-up, choroidal neovascularization closure was obtained in all eyes. An improvement of functional parameters was recorded in all patients (best-corrected visual acuity from 25.5 ± 8.09 letters to 45.5 ± 8.16 letters, P <0.0001; microperimetry from 8.40 ± 2.14 dB to 10.8 ± 2.05 dB, P <0.01). The mean number of IVP was 3, and none of patients met the re-treatment criterion during the entire follow-up period. Neither ocular nor systemic side effects were observed. CONCLUSION:: The findings demonstrate that the selective inhibition of VEGF-165 isoform by IVP is an effective treatment for myopic choroidal neovascularization.

Original languageEnglish
Pages (from-to)397-402
Number of pages6
JournalRetina
Volume33
Issue number2
DOIs
Publication statusPublished - Feb 2013

Keywords

  • best visual acuity
  • foveal central thickness
  • microperimetry
  • myopic choroidal neovascularization
  • pegaptanib

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Intravitreal pegaptanib sodium (Macugen) for treatment of myopic choroidal neovascularization: A morphologic and functional study'. Together they form a unique fingerprint.

  • Cite this

    Rinaldi, M., Chiosi, F., Dellêomo, R., Romano, M. R., Parmeggiani, F., Semeraro, F., Menzione, M., & Costagliola, C. (2013). Intravitreal pegaptanib sodium (Macugen) for treatment of myopic choroidal neovascularization: A morphologic and functional study. Retina, 33(2), 397-402. https://doi.org/10.1097/IAE.0b013e318261a73c